Skip to content
Olumiant(baricitinib)
Olumiant (baricitinib) is a small molecule pharmaceutical. Baricitinib was first approved as Olumiant on 2017-02-13. It is used to treat rheumatoid arthritis in the USA. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against tyrosine-protein kinase JAK1 and tyrosine-protein kinase JAK2. In addition, it is known to target cyclin-G-associated kinase, non-receptor tyrosine-protein kinase TYK2, BMP-2-inducible protein kinase, AP2-associated protein kinase 1, and tyrosine-protein kinase JAK3.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
Olumiant
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Baricitinib
Tradename
Company
Number
Date
Products
OLUMIANTEli LillyN-207924 RX2018-05-31
3 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
olumiantNew Drug Application2020-11-19
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
rheumatoid arthritisEFO_0000685D001172M06.9
Agency Specific
FDA
EMA
Expiration
Code
BARICITINIB, OLUMIANT, ELI LILLY AND CO
2025-06-13I-890
2025-05-10I-891
2023-05-31NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Baricitinib, Olumiant, Eli Lilly And Co
90895742032-11-30U-3372
110454742032-11-30U-3372
97374692031-11-02U-3500
81586162030-06-08DS, DP
84206292029-03-10U-247
ATC Codes
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AA: Selective immunosuppressants
— L04AA37: Baricitinib
HCPCS
No data
Clinical
Clinical Trials
124 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Rheumatoid arthritisD001172EFO_0000685M06.91495423
Covid-19D000086382U07.1—6111419
Psoriatic arthritisD015535EFO_0003778L40.5———1—1
SpondylarthritisD025241———1—1
Systemic sclerodermaD012595EFO_0000717M34———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atopic dermatitisD003876EFO_0000274L20—18—110
Systemic lupus erythematosusD008180EFO_0002690M32—13——4
PneumoniaD011014EFO_0003106J18—32——4
DermatomyositisD003882EFO_0000398M33—21—14
Juvenile arthritisD001171EFO_0002609M08——3——3
Alopecia areataD000506EFO_0004192L63—13——3
Skin diseasesD012871L00-L99—21——3
Respiratory distress syndromeD012128EFO_1000637J80—12——2
LipodystrophyD008060E88.1—11—12
UveitisD014605EFO_1001231H20.9——1——1
Show 7 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Graft vs host diseaseD006086D89.8121———2
PsoriasisD011565EFO_0000676L40—1——12
Sjogren's syndromeD012859EFO_0000699M35.012———2
VitiligoD014820EFO_0004208L80—1———1
Type 1 diabetes mellitusD003922EFO_0001359E10—1———1
Sars-cov-2D000086402—1———1
MyositisD009220EFO_0000783G72.49—1———1
Biliary liver cirrhosisD008105K74.3—1———1
Giant cell arteritisD013700EFO_1001209M31.6—1———1
Diabetic nephropathiesD003928EFO_0000401—1———1
Show 12 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—16————16
Allergic contact dermatitisD017449L231————1
Liver diseasesD008107EFO_0001421K70-K771————1
Hepatic insufficiencyD0485501————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Respiratory insufficiencyD012131HP_0002093J96.9————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBARICITINIB
INNbaricitinib
Description
Baricitinib is a pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine substituted by a 1-[3-(cyanomethyl)-1-(ethanesulfonyl)azetidin-3-yl]-1H-pyrazol-4-yl group at position 5. It is an FDA approved selective Janus Kinase 1 and 2 (JAK1 and JAK2) inhibitor used for the treatment of rheumatoid arthritis. It has a role as an antirheumatic drug, an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor, an anti-inflammatory agent, an immunosuppressive agent and an antiviral agent. It is a pyrrolopyrimidine, a member of pyrazoles, a member of azetidines, a sulfonamide and a nitrile.
Classification
Small molecule
Drug classtyrosine kinase inhibitors: tyrosine kinase inhibitors; janus kinase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Identifiers
PDB4W9X
CAS-ID1187594-09-7
RxCUI2047232
ChEMBL IDCHEMBL2105759
ChEBI ID—
PubChem CID44205240
DrugBankDB11817
UNII IDISP4442I3Y (ChemIDplus, GSRS)
Target
Agency Approved
JAK1
JAK1
JAK2
JAK2
Organism
Homo sapiens
Gene name
JAK1
Gene synonyms
JAK1A, JAK1B
NCBI Gene ID
3716
Protein name
tyrosine-protein kinase JAK1
Protein synonyms
JAK-1, Janus kinase 1
Uniprot ID
Q9UD26
Mouse ortholog
Jak1 (16451)
tyrosine-protein kinase JAK1 (P52332)
Alternate
GAK
GAK
TYK2
TYK2
BMP2K
BMP2K
AAK1
AAK1
JAK3
JAK3
Organism
Homo sapiens
Gene name
GAK
Gene synonyms
NCBI Gene ID
2580
Protein name
cyclin-G-associated kinase
Protein synonyms
auxilin-2
Uniprot ID
O14976
Mouse ortholog
Gak (231580)
cyclin-G-associated kinase (Q99KY4)
Variants
Clinical Variant
No data
Financial
Olumiant - Eli Lilly
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Olumiant - Incyte
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 7,001 documents
View more details
Safety
Black-box Warning
Black-box warning for: Olumiant
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,509 adverse events reported
View more details